That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Quantum BioPharma Ltd., a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, will attend the ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026. Anthony Durkacz, Co-founder and Executive Co-chairman of Quantum BioPharma, will discuss recent achievements and future plans during his presentation. Recently, the company received FDA approval for its Investigational New Drug application for Lucid-MS, a first-in-class multiple sclerosis treatment set to begin Phase 2 trials. The global MS therapeutics market is expected to reach $38.62 billion by 2030, according to Grand View Research.
Written by the local model on 2026-09-16,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
Quantum BioPharma Ltd., a biopharmaceutical company focused on treating neurodegenerative and metabolic disorders, will attend the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026 at the Sheraton Center Toronto Hotel. Anthony Durkacz, co-founder and executive co-chairman of Quantum BioPharma, is scheduled to present on the company’s recent achievements and future plans. Recently, Quantum BioPharma announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application for Lucid-MS, enabling Phase 2 trials in progressive multiple sclerosis patients, an area with significant unmet medical needs globally.
Written for “Quantum Biopharma Conference Attendance” on 2026-09-17,
grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
This article does not take a side on a contested political
question, so it has no leaning score. That is an
answer rather than a gap: a match report or a rescue can be warmly
or critically written without being left or right, and scoring it
anyway is how approval of a subject gets recorded as a political
position.
No political leaning scored for article 10802 · logged 2026-09-16
Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel.
asserted
Ltd. → dedicate → Hotel
Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.
asserted
Durkacz → present → milestones
Recently Quantum BioPharma announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application for Lucid-MS, to begin Phase 2 trials for the very first time to advance its patented, first-in-class multiple sclerosis (“MS”) program in patients with progressive MS.
asserted
Administration → announce → MS
This is currently an area of substantial unmet medical need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030 (Grand View Research, 2026).
asserted
This → anticipate → Research
The Aporia
